创胜集团－Ｂ(06628.HK)治疗实体瘤药物临床试验申请获FDA批准_老虎社区_美港股上老虎

创胜集团－Ｂ(06628.HK)治疗实体瘤药物临床试验申请获FDA批准

AAFN2022-09-14

创胜集团－Ｂ公布，公司的同类首创，靶向Gremlin1且具有人源化单克隆抗体TST003的临床试验申请获美国食品药品监督管理局(FDA)批准。Gremlin1是一种在多种人类癌症，例如食管癌、胰腺癌、胃癌等的基质细胞中高度表达的调节蛋白，且与肿瘤形成有关联，能促进癌细胞的增殖、迁移、侵袭和转移。在临床前研究中，TST003在体外及体内均表现出显着的抗肿瘤活性。TST003有望成为一种新型癌症...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2267759691?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2022-09-14 12:01","share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","id":"2267759691","market":"us","top_or_hot":-1,"title":"创胜集团－Ｂ(06628.HK)治疗实体瘤药物临床试验申请获FDA批准","media":"AAFN","content":"<div>\n<p>创胜集团－Ｂ  公布，公司的同类首创，靶向Gremlin1且具有人源化单克隆抗体TST003的临床试验申请获美国食品药品监督管理局(FDA)批准。Gremlin1是一种在多种人类癌症，例如食管癌、胰腺癌、胃癌等的基质细胞中高度表达的调节蛋白，且与肿瘤形成有关联，能促进癌细胞的增殖、迁移、侵袭和转移。在临床前研究中，TST003在体外及体内均表现出显着的抗肿瘤活性。TST003有望成为一种新型癌症...</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1213262&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">网页链接</a>\n\n</div>\n","source":"aastocks","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>创胜集团－Ｂ(06628.HK)治疗实体瘤药物临床试验申请获FDA批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n创胜集团－Ｂ(06628.HK)治疗实体瘤药物临床试验申请获FDA批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-14 12:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1213262&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0><strong>AAFN</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>创胜集团－Ｂ  公布，公司的同类首创，靶向Gremlin1且具有人源化单克隆抗体TST003的临床试验申请获美国食品药品监督管理局(FDA)批准。Gremlin1是一种在多种人类癌症，例如食管癌、胰腺癌、胃癌等的基质细胞中高度表达的调节蛋白，且与肿瘤形成有关联，能促进癌细胞的增殖、迁移、侵袭和转移。在临床前研究中，TST003在体外及体内均表现出显着的抗肿瘤活性。TST003有望成为一种新型癌症...</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1213262&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06628","symbol_name":"创胜集团-B","start_time":0,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1213262&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","article_id":"2267759691","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2267759691","pubTimestamp":1663128118,"columns":[],"sourceInfo":{"source_id":"aastocks","name":"阿思达克财经"},"weMediaInfo":null,"summary":"创胜集团－Ｂ  公布，公司的同类首创，靶向Gremlin1且具有人源化单克隆抗体TST003的临床试验申请获美国食品药品监督管理局(FDA)批准。Gremlin1是一种在多种人类癌症，例如食管癌、胰腺癌、胃癌等的基质细胞中高度表达的调节蛋白，且与肿瘤形成有关联，能促进癌细胞的增殖、迁移、侵袭和转移。在临床前研究中，TST003在体外及体内均表现出显着的抗肿瘤活性。TST003有望成为一种新型癌症治疗方法，可作为单药疗法或与免疫检查点抑制剂及或其他抗肿瘤药物联用。(ha/k)~阿思达克财经新闻网址: www.aastocks.com","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"06628":"创胜集团-B","BK1161":"生物科技"},"translate_title":"The application for clinical trial of Chuangsheng Group-B (06628. HK) drugs for treating solid tumors was approved by FDA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06628":0.9},"content_text":"创胜集团－Ｂ  公布，公司的同类首创，靶向Gremlin1且具有人源化单克隆抗体TST003的临床试验申请获美国食品药品监督管理局(FDA)批准。Gremlin1是一种在多种人类癌症，例如食管癌、胰腺癌、胃癌等的基质细胞中高度表达的调节蛋白，且与肿瘤形成有关联，能促进癌细胞的增殖、迁移、侵袭和转移。在临床前研究中，TST003在体外及体内均表现出显着的抗肿瘤活性。TST003有望成为一种新型癌症治疗方法，可作为单药疗法或与免疫检查点抑制剂及或其他抗肿瘤药物联用。(ha/k)~阿思达克财经新闻网址: www.aastocks.com","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}